Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 8/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | AR | P10275 | 6/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.67 |
| ▸ | ESR1 | P03372 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | SHBG | P04278 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.66 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30496613 | 1.00 | PGR (0.67) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL25863263 | 1.00 | PGR (0.67) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL20927509 | 1.00 | PGR (0.67) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL8853386 | 0.95 | PGR (0.65) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11694584 | 0.94 | PGR (0.64) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL8853332 | 0.94 | PGR (0.64) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL25863273 | 0.93 | PGR (0.63) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL11694580 | 0.93 | PGR (0.63) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL25863267 | 0.93 | PGR (0.63) | PGRLMNAARSLC6A4CYP3A4 | |
| SCHEMBL25863269 | 0.93 | PGR (0.63) | PGRLMNAARSLC6A4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | claimed |
| US-20250235468-A1 | FORMULATION OF LONG-ACTING LEVONORGESTREL BUTANOATE INJECTABLE DEPOT SUSPENSION | EASTERN VIRGINIA MEDICAL SCHOOL | 2025-07-24 | — | — | US | claimed |
| US-20250170145-A1 | FORMULATION OF LONG-ACTING LEVONORGESTREL BUTANOATE INJECTABLE DEPOT SUSPENSION | EASTERN VIRGINIA MEDICAL SCHOOL | 2025-05-29 | — | — | US | claimed |
| US-20250161323-A1 | FORMULATION OF LONG-ACTING LEVONORGESTREL BUTANOATE INJECTABLE DEPOT SUSPENSION | EASTERN VIRGINIA MEDICAL SCHOOL | 2025-05-22 | — | — | US | claimed |
| US-12290523-B2 | Formulation of long-acting levonorgestrel butanoate injectable depot suspension | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2025-05-06 | — | — | US | claimed |
| US-20250041315-A1 | LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-02-06 | — | — | US | claimed |
| EP-4447931-A1 | LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-10-23 | — | — | EP | claimed |
| CN-118488830-A | Levonorgestrel butyrate formulations and methods relating thereto | 美国政府(由卫生和人类服务部的部长所代表) | 2024-08-13 | — | — | CN | claimed |
| WO-2023114205-A1 | LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-22 | — | — | WO | claimed |
| EP-3773730-A1 | DRUG DELIVERY FORMULATIONS | The Regents of The University of California (US) | 2021-02-17 | — | — | EP | claimed |
| US-20210000744-A1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2021-01-07 | — | — | US | claimed |
| US-20190328749-A1 | FORMULATION OF LONG-ACTING LEVONORGESTREL BUTANOATE INJECTABLE DEPOT SUSPENSION | EASTERN VIRGINIA MEDICAL SCHOOL | 2019-10-31 | — | — | US | claimed |
| WO-2019191132-A1 | DRUG DELIVERY FORMULATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-03 | — | — | WO | claimed |
| EP-3419604-A1 | AN IMPROVED FORMULATION OF LONG-ACTING LEVONORGESTREL BUTANOATE INJECTABLE DEPOT SUSPENSION | Eastern Virginia Medical School (US) | 2019-01-02 | — | — | EP | claimed |
| US-20170290846-A1 | IN SITU GELLING FORM FOR LONG-ACTING DRUG DELIVERY | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2017-10-12 | — | — | US | claimed |
| WO-2017147274-A1 | AN IMPROVED FORMULATION OF LONG-ACTING LEVONORGESTREL BUTANOATE INJECTABLE DEPOT SUSPENSION | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2017-08-31 | — | — | WO | claimed |
| WO-2016054197-A1 | IN SITU GELLING FORM FOR LONG-ACTING DRUG DELIVERY | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-04-07 | — | — | WO | claimed |
| EP-3773730-B1 | DRUG DELIVERY FORMULATIONS | UNIV CALIFORNIA (US) | 2026-05-13 | — | — | EP | disclosed |
| WO-2006113505-A2 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPRISING SAME | CLARUS THERAPEUTICS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-5595759-A | Process for providing therapeutic composition | ALZA CORPORATION (US) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000744-A1 | DRUG DELIVERY FORMULATIONS | PGR, FKBP1A, LPXN | PGR 1/4885LMNA 1651/4885AR 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.